Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactococcus lactis W136 (Probionase Therapies)
- Development stage
- Unknown
- Lead developer
- Probionase Therapies
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intranasal
01
Overview
Lactococcus lactis W136 is a live biotherapeutic product (LBP) consisting of a specific strain of lactic acid bacteria, developed by Probionase Therapies for the treatment of chronic rhinosinusitis (CRS). Administered via intranasal irrigation, the therapy aims to address the sinonasal dysbiosis frequently observed in CRS patients, which is characterized by a reduction in beneficial commensal bacteria and an overrepresentation of pathogens such as Staphylococcus aureus. Lactococcus lactis W136 works by competitively excluding pathogenic species, producing antimicrobial metabolites such as lactic acid or bacteriocins, and potentially modulating the host's mucosal immune response to reduce inflammation. A Phase 1 clinical trial has evaluated the safety and tolerability of this intranasal probiotic irrigation in healthy volunteers to support its further development for CRS.
- Other names
- Lactococcus lactis strain W136Probionase
Beyond the preview
Go deeper on Lactococcus lactis W136 (Probionase Therapies).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactococcus lactis W136 (Probionase Therapies).